These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15330194)

  • 1. Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor.
    Yamaguchi T; Bamba K; Kitayama A; Kuroiwa Y; Yoshimatsu K; Shimakawa T; Ogawa K; Sekine T; Shimizu N; Yamamoto K
    Anticancer Res; 2004; 24(4):2423-9. PubMed ID: 15330194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
    Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells.
    Yamaguchi Y; Ohshita A; Hironaka K; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hihara J
    Oncol Rep; 2006 Jul; 16(1):165-9. PubMed ID: 16786141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels.
    Ebina T; Ogama N; Shimanuki H; Kubota T; Isono N
    Cancer Immunol Immunother; 2003 Sep; 52(9):555-60. PubMed ID: 14627127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
    Homma S; Sagawa Y; Ito M; Ohno T; Toda G
    Clin Exp Immunol; 2006 Apr; 144(1):41-7. PubMed ID: 16542363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis.
    van Laar JM; Miltenburg AM; Verdonk MJ; Leow A; Elferink BG; Daha MR; Cohen IR; de Vries RR; Breedveld FC
    J Autoimmun; 1993 Apr; 6(2):159-67. PubMed ID: 8098938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion.
    Toh U; Fujii T; Seki N; Niiya F; Shirouzu K; Yamana H
    Cancer Immunol Immunother; 2006 Oct; 55(10):1219-27. PubMed ID: 16362409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
    Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
    Thistlethwaite FC; Elkord E; Griffiths RW; Burt DJ; Shablak AM; Campbell JD; Gilham DE; Austin EB; Stern PL; Hawkins RE
    Cancer Immunol Immunother; 2008 May; 57(5):623-34. PubMed ID: 17899077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
    Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
    Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
    Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
    Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation.
    Wu F; Wang ZB; Lu P; Xu ZL; Chen WZ; Zhu H; Jin CB
    Ultrasound Med Biol; 2004 Sep; 30(9):1217-22. PubMed ID: 15550325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.